[go: up one dir, main page]

WO2011153345A3 - A gene expression profile of brca-ness that correlates with responsiveness to chemotherapy and with outcome in cancer patients - Google Patents

A gene expression profile of brca-ness that correlates with responsiveness to chemotherapy and with outcome in cancer patients Download PDF

Info

Publication number
WO2011153345A3
WO2011153345A3 PCT/US2011/038922 US2011038922W WO2011153345A3 WO 2011153345 A3 WO2011153345 A3 WO 2011153345A3 US 2011038922 W US2011038922 W US 2011038922W WO 2011153345 A3 WO2011153345 A3 WO 2011153345A3
Authority
WO
WIPO (PCT)
Prior art keywords
gene expression
expression profile
brca
ness
responsiveness
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/038922
Other languages
French (fr)
Other versions
WO2011153345A2 (en
Inventor
Stephen Cannistra
Panagiotis Konstantinopoulos
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beth Israel Deaconess Medical Center Inc
Original Assignee
Beth Israel Deaconess Medical Center Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beth Israel Deaconess Medical Center Inc filed Critical Beth Israel Deaconess Medical Center Inc
Publication of WO2011153345A2 publication Critical patent/WO2011153345A2/en
Publication of WO2011153345A3 publication Critical patent/WO2011153345A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Aspects of the invention provide methods and compositions for evaluating cells and tissues based on gene expression profiles to determine their sensitivity or resistance to one or more chemotherapeutic agents. A patient having a tumor or cancer can be evaluated using a gene expression profile to assist in determining the disease prognosis, selecting an appropriate therapy, and/or predicting drug resistance or sensitivity.
PCT/US2011/038922 2010-06-03 2011-06-02 A gene expression profile of brca-ness that correlates with responsiveness to chemotherapy and with outcome in cancer patients Ceased WO2011153345A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35128210P 2010-06-03 2010-06-03
US61/351,282 2010-06-03

Publications (2)

Publication Number Publication Date
WO2011153345A2 WO2011153345A2 (en) 2011-12-08
WO2011153345A3 true WO2011153345A3 (en) 2012-03-15

Family

ID=45067295

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/038922 Ceased WO2011153345A2 (en) 2010-06-03 2011-06-02 A gene expression profile of brca-ness that correlates with responsiveness to chemotherapy and with outcome in cancer patients

Country Status (1)

Country Link
WO (1) WO2011153345A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170058351A1 (en) * 2013-11-28 2017-03-02 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Methods for Molecular Classification of BRCA-Like Breast and/or Ovarian Cancer
WO2016106340A2 (en) * 2014-12-23 2016-06-30 Genentech, Inc. Compositions and methods for treating and diagnosing chemotherapy-resistant cancers
WO2016185406A1 (en) 2015-05-19 2016-11-24 Nadathur Estates Pvt. Ltd. Method for identification of a deficient brca1 function
CA3074985A1 (en) 2017-10-16 2019-04-25 Dana-Farber Cancer Institute, Inc. Compounds and methods for treating cancer
US12083189B2 (en) 2022-04-29 2024-09-10 Tiba Biotech, Llc Tail-conjugated RNAs

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060246470A1 (en) * 2004-12-06 2006-11-02 Suzanne Fuqua RNA expression profile predicting response to tamoxifen in breast cancer patients

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060246470A1 (en) * 2004-12-06 2006-11-02 Suzanne Fuqua RNA expression profile predicting response to tamoxifen in breast cancer patients

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MARKMAN ET AL.: "Second-Line Treatment of Ovarian Cancer", THE ONCOLOGIST, vol. 5, no. 1, 2000, pages 26 - 35 *

Also Published As

Publication number Publication date
WO2011153345A2 (en) 2011-12-08

Similar Documents

Publication Publication Date Title
Nagel et al. Inter-individual variation in DNA repair capacity: a need for multi-pathway functional assays to promote translational DNA repair research
NZ607282A (en) Method for using gene expression to determine prognosis of prostate cancer
BRPI0917871A2 (en) anti-erbb3 therapeutic agent for use in tumor therapy, methods for predicting tumor responsiveness of an anti-erbb3 therapeutic agent, for selecting anti-erbb3 therapy for a patient, for predicting cell response to treatment with a therapeutic agent , to identify a biomarker, and to prevent administration of an anti-erbb3 cancer drug, and kit to predict cell response to treatment with a therapeutic agent
WO2013166186A8 (en) Method for determining complete response to anticancer therapy
MX343801B (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer.
MX339427B (en) Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer.
HK1255533A1 (en) Protein biomarker panels for detecting colorectal cancer and advanced adenoma
WO2011088137A3 (en) Bad pathway gene signature
WO2012135592A3 (en) Theranostic imaging agents and methods of use
MX2015014486A (en) Markers of tumor cell response to anti-cancer therapy.
WO2008106175A3 (en) Gene and protein expression profiles associated with the therapeutic efficacy of egfr-tk inhibitors
HK1201881A1 (en) Gene expression profile algorithm and test for determining prognosis of prostate cancer
MX2009002936A (en) Biomarkers of target modulation, efficacy, diagnosis and/or prognosis for raf inhibitors.
EP2908132A3 (en) Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures
EP3236262A3 (en) Surrogate functional diagnostics test for cancer
NZ617003A (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
BR112012020373A2 (en) isolated antibody, cell, isolated nucleic acid, method of identification, cell proliferation inhibition, therapeutic treatment, determination of the presence of a tata419 protein, diagnosis of the presence of cancer and distribution of cytotoxic agent
EP2198021A4 (en) Ebi3, dlx5, nptx1 and cdkn3 for target genes of lung cancer therapy and diagnosis
WO2009094647A3 (en) P53 biomarkers
WO2011153345A3 (en) A gene expression profile of brca-ness that correlates with responsiveness to chemotherapy and with outcome in cancer patients
MX2012007940A (en) Tumor tissue based biomarkers for bevacizumab combination therapies.
BR112014027905A2 (en) antibody, cell, nucleic acid, methods of identifying a first antibody, inhibiting cell growth, therapeutic treatment, determining the presence of a protein, diagnosing a tumor, and delivering a cytotoxic agent.
WO2013071012A3 (en) Personalized strategic cancer treatment
NZ748624A (en) Methods of selecting an individual who will benefit from treatment with a telomerase inhibitor using a formalin fixed paraffin embedded (ffpe) biological sample of solid tumor cancer cells
WO2008095049A3 (en) Reagents and methods for predicting drug resistance

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11790404

Country of ref document: EP

Kind code of ref document: A2